Related Experiment Video
Updated: Jun 10, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Recalcitrant atopic dermatitis treated with omalizumab.
Se-Young Park1, Mi-Ra Choi, Jung-Im Na
1Department of Dermatology, Seoul National University College of Medicine, Seongnam, Korea.
Annals of Dermatology
|August 17, 2010
Summary
Omalizumab, a novel biologic therapy, effectively treated a patient with severe, refractory atopic dermatitis (AD). This case study highlights its potential for managing difficult-to-treat AD cases with high IgE levels.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition with limited treatment options for severe, refractory cases.
- Elevated immunoglobulin E (IgE) levels are common in AD and correlate with disease severity.
- Omalizumab, a monoclonal anti-IgE antibody, targets IgE and has shown efficacy in allergic diseases.
Observation:
- A 34-year-old male patient presented with severe, recalcitrant AD refractory to multiple topical and oral therapies.
- The patient exhibited significantly elevated serum IgE levels.
- Treatment with omalizumab was initiated due to the patient's refractory condition and high IgE.
Findings:
- After 8 months of omalizumab treatment, the patient experienced notable improvement in AD symptoms.
- The SCORAD (Severity of Atopic Dermatitis) index significantly decreased, indicating reduced disease severity.
- This represents the first reported successful use of omalizumab for recalcitrant AD in Korea.
Implications:
- Omalizumab demonstrates potential as a systemic treatment for severe, refractory atopic dermatitis in patients with elevated IgE.
- This case suggests omalizumab may be a valuable therapeutic option for patients unresponsive to conventional treatments.
- Further research and clinical trials are warranted to confirm the efficacy and safety of omalizumab in a broader AD population.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...